The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
NetMHCphosPan - Pan-specific prediction of MHC class I antigen presentation of phosphorylated ligands
Open accessAbstract
Post-translational modifications of proteins play a crucial part in carcinogenesis. Phosphorylated peptides have shown to be presented by MHC class I molecules and recognised by cytotoxic T cells, making them a promising target for immunotherapy. Identification of phosphorylated MHC class I ligands has so far predominantly been done using bioinformatic tools trained on unmodified peptides. Only one tool, PhosMHCpred, has been developed specifically for the prediction of phosphorylated MHC class I ligands so far and this tool has been trained only on a limited number of alleles and provides a limited peptide length coverage (only including 9-mers). Here we propose a method, termed NetMHCphosPan, for the prediction of MHC presented phosphopeptides. The method is trained using the NNAlign_MA framework, which allows incorporating mixed data types and information leverage between data sets resulting in a greatly improved MHC and peptide length coverage and an overall increased predictive power compared to PhosMHCpred. Motif deconvolution suggested a strong preference for phosphosites to be located in position 4 of the binding motif, and enrichment of proline at P5 and arginine at P1. The improved performance, driven by the extended length and allelic coverage, of NetMHCphosPan over current state-of-the-art methods, was further validated on a large benchmark data set independent from the model development. In conclusion, we have confirmed the high power of NNAlign_MA for motif deconvolution of complex immuno-peptidomics data and have developed a novel method for prediction of MHC presented phosphopeptides with improved predictive power and a broader peptide length and MHC coverage compared to current state-of-the-art methods. The developed method is available at http://www.cbs.dtu.dk/services/NetMHCphosPan-1.0.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044
Flagged first, then by citations
Research works printed but not linked: 27
- Andersen, 1999, Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL, J Immunol Baltim Md 1950. 1. oktober, 163, 3812
- Zarling, 2000, Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo, J Exp Med, 192, 1755, 10.1084/jem.192.12.1755 · DOI · Paper page
- Zarling, 2006, Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy, Proc Natl Acad Sci. 3. oktober, 103, 14889, 10.1073/pnas.0604045103 · DOI
- Robinson, 2019, IPD-IMGT/HLA database, Nucleic Acids Res., 31, gkz950, 10.1093/nar/gkz950 · DOI
- Nielsen, 2020, Immunoinformatics: predicting peptide–MHC binding, Annu Rev Biomed Data Sci. 20. juli, 3, 191, 10.1146/annurev-biodatasci-021920-100259 · DOI
- Alpízar, 2017, A molecular basis for the presentation of phosphorylated peptides by HLA-B antigens, Mol Cell Proteomics MCP. februar, 16, 181, 10.1074/mcp.M116.063800 · DOI
- Meyer, 2009, Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands, J Proteome Res. 6. juli, 8, 3666, 10.1021/pr800937k · DOI
- Cobbold, 2013, MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia, Sci Transl Med, 5, 10.1126/scitranslmed.3006061 · DOI
- Marcilla, 2014, Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue*, Mol Cell Proteomics. februar, 13, 462, 10.1074/mcp.M113.034314 · DOI
- Bassani-Sternberg, 2016, Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry, Nat Commun, 7, 13404, 10.1038/ncomms13404 · DOI · Paper page
- Abelin, 2017, Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction, Immunity. februar, 46, 315, 10.1016/j.immuni.2017.02.007 · DOI
- Mohammed, 2008, Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self, Nat Immunol, 9, 1236, 10.1038/ni.1660 · DOI · Paper page
- Mohammed, 2017, The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status, Oncotarget, 8, 54160, 10.18632/oncotarget.16952 · DOI
- Mommen, 2014, Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD), Proc Natl Acad Sci. 25. marts, 111, 4507, 10.1073/pnas.1321458111 · DOI
- Solleder, 2020, Mass spectrometry based immunopeptidomics leads to robust predictions of phosphorylated HLA Class I Ligands, Mol Cell Proteomics MCP. februar, 19, 390, 10.1074/mcp.TIR119.001641 · DOI · Paper page
- Alvarez, 2019, NNAlign_MA; MHC peptidome deconvolution for accurate MHC binding motif characterization and improved T-cell epitope predictions, Mol Cell Proteomics, 18, 2459, 10.1074/mcp.TIR119.001658 · DOI
- Hornbeck, 2015, PhosphoSitePlus, 2014: mutations, PTMs and recalibrations, Nucleic Acids Res. januar, 43, D512, 10.1093/nar/gku1267 · DOI · Paper page
- Reynisson, 2020, NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data, Nucleic Acids Res. 2. juli, 48, W449, 10.1093/nar/gkaa379 · DOI · Paper page
- Nielsen, 2007, Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method, BMC Bioinformatics. 4. juli, 8, 238, 10.1186/1471-2105-8-238 · DOI
- Mei, 2020, Immunopeptidomic analysis reveals that deamidated HLA-bound peptides arise predominantly from deglycosylated precursors, Mol Cell Proteomics. juli, 19, 1236, 10.1074/mcp.RA119.001846 · DOI
- Purcell, 2019, Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics, Nat Protoc. juni, 14, 1687, 10.1038/s41596-019-0133-y · DOI
- Wagih, 2017, ggseqlogo: a versatile R package for drawing sequence logos, Hancock J, redaktør. Bioinformatics, 33, 3645, 10.1093/bioinformatics/btx469 · DOI
- Sharma, 2014, Ultradeep Human Phosphoproteome Reveals a Distinct Regulatory Nature of Tyr and Ser/Thr-Based Signaling, Cell Rep, 8, 1583, 10.1016/j.celrep.2014.07.036 · DOI
- Fenoy, 2019, A generic deep convolutional neural network framework for prediction of receptor-ligand interactions-NetPhosPan: application to kinase phosphorylation prediction, Bioinforma Oxf Engl, 35, 1098, 10.1093/bioinformatics/bty715 · DOI
- Hoof, 2009, NetMHCpan, a method for MHC class I binding prediction beyond humans, Immunogenetics. januar, 61, 1, 10.1007/s00251-008-0341-z · DOI
- Leko, 2020, Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors, Cancer Cell. 12. oktober, 38, 454, 10.1016/j.ccell.2020.07.013 · DOI · Paper page
- Engelhard, 2020, MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma, J Immunother Cancer. maj, 8
Metadata
- Authors
- Refsgaard, C. T., Barra, C., Peng, X., Ternette, N., & Nielsen, M.
- Affiliations
- Technical University of Denmark (DK)
- University of Oxford (GB)
- National University of General San Martín (AR)
- Corresponding author
- Nielsen, Morten
- Venue
- ImmunoInformatics
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 1-2
- Pages
- 100005
- ISSN
- 2667-1190 (ISSN-L)
- OpenAlex
- W3195507843
- Cited by
- 12
- References
- 1
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- ImmunoInformatics (publishedVersion, cc-by-nc-nd)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (HHSN272201200010C)
- National Institutes of Health
- U.S. Department of Health and Human Services
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- MHC class I antigen presentation, phosphopeptides, post-translational modification, MHC alleles, cancer immunotherapy, cytotoxic T lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review